[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Curanex Pharmaceuticals Inc (CURX)

Curanex Pharmaceuticals Inc (CURX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,532
  • Shares Outstanding, K 28,365
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,230 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.27
  • Most Recent Earnings $-0.11 on 05/14/26
  • Next Earnings Date 09/08/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3000 +0.67%
on 05/19/26
0.4904 -38.42%
on 04/23/26
-0.1490 (-33.04%)
since 04/17/26
3-Month
0.2953 +2.27%
on 02/23/26
0.6666 -54.70%
on 02/26/26
-0.0178 (-5.57%)
since 02/19/26

Most Recent Stories

More News
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

NEW YORK , May 18, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals...

CURX : 0.3020 (+0.40%)
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated...

CURX : 0.3020 (+0.40%)
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

NEW YORK , May 12, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals...

CURX : 0.3020 (+0.40%)
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)...

CURX : 0.3020 (+0.40%)
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) resulting from...

CURX : 0.3020 (+0.40%)
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple critically...

CURX : 0.3020 (+0.40%)
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most serious and underserved supportive-care markets ...

CURX : 0.3020 (+0.40%)
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company

Company expands strategic focus into one of oncology’s  most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)...

CURX : 0.3020 (+0.40%)
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex...

CURX : 0.3020 (+0.40%)
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March ...

CURX : 0.3020 (+0.40%)

Business Summary

Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases. Its lead candidate includes Phyto-N. Curanex Pharmaceuticals Inc. is headquartered in Jericho, New York.

See More

Key Turning Points

3rd Resistance Point 0.3233
2nd Resistance Point 0.3183
1st Resistance Point 0.3101
Last Price 0.3020
1st Support Level 0.2969
2nd Support Level 0.2919
3rd Support Level 0.2837

See More

52-Week High 9.1796
Fibonacci 61.8% 5.7731
Fibonacci 50% 4.7208
Fibonacci 38.2% 3.6685
Last Price 0.3020
52-Week Low 0.2620

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.